Atlas Trials

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Clinical trial NCT04634877 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04634877
Sponsor
Merck Sharp & Dohme LLC
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Endometrial Neoplasms
Start date
2021-01-10
Primary completion
2026-09-15
Enrollment
990

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.